H.R. 2159 — A bill to reduce disparities and improve access to effective and cost efficient diagnosis and treatment of prostate cancer through advances in testing, research, and education, including through telehealth, comparative effectiveness research, and identification of best practices in patient education and outreach particularly with respect to underserved racial, ethnic and rural populations and men with a family history of prostate cancer, to establish a directive on what constitutes clinically appropriate prostate cancer imaging, and to create a prostate cancer scientific advisory board for the Office of the Chief Scientist at the Food and Drug Administration to accelerate real-time sharing of the latest research and accelerate movement of new medicines to patients; to the Committee on Energy and Commerce, and in addition to the Committees on Veterans’ Affairs, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
By Mr. TOWNS (for himself, Mr. Broun of Georgia, Ms. Fudge, Ms. Richardson, Mr. Gerlach, Ms. Moore, Mr. McIntyre, Mr. Rangel, Ms. Eddie Bernice Johnson of Texas, Ms. Wilson of Florida, Ms. Norton, Mr. Thompson of Mississippi, Mr. Carson of Indiana, Ms. Lee of California, Mr. Israel, and Mr. King of New York), H4185 [14JN]
Cosponsors added, H4530 [23JN], H4673 [6JY], H5087 [14JY], H5127 [15JY], H5375 [21JY], H5734 [28JY], H6273 [20SE], H6415 [22SE], H6458 [23SE], H6626 [5OC], H7009 [24OC], H8187 [6DE], H9946 [19DE], H10016 [20DE]